Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31843
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ackermann, Uwe | - |
dc.contributor.author | Jäger, Luise | - |
dc.contributor.author | Rigopoulos, Angela | - |
dc.contributor.author | Burvenich, Ingrid Julienne Georgette | - |
dc.contributor.author | O'Keefe, Graeme Joseph | - |
dc.contributor.author | Scott, Andrew M | - |
dc.date | 2022 | - |
dc.date.accessioned | 2023-01-12T04:50:28Z | - |
dc.date.available | 2023-01-12T04:50:28Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Nuclear Medicine and Biology 2023; 116-117 | en_US |
dc.identifier.issn | 1872-9614 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/31843 | - |
dc.description.abstract | Tissue transglutaminase 2 (TG2) is a calcium-dependent enzyme which cross-links proteins. It is overexpressed in many diseases and plays a key role in tissue remodeling, including cell adhesion and migration. Overexpression of TG2 in breast cancer is a marker for patients at risk of recurrence. Non-invasive imaging of TG2 can therefore play an important role in patient management. TG2 probes labeled with the positron emitters 11C and 18F have thus far not found widespread application due to purity and metabolism issues. Our approach was to radiolabel a TG2 selective, 13-mer amino acid peptide, which was modified with a 5-azidopentanoic acid group at the N-terminus via a copper free click chemistry approach. | en_US |
dc.language.iso | eng | - |
dc.subject | Fluorine-18 | en_US |
dc.subject | Hitomi peptide | en_US |
dc.subject | PET imaging | en_US |
dc.subject | Transglutaminase 2 | en_US |
dc.title | 18F-labeling and initial in vivo evaluation of a Hitomi peptide for imaging tissue transglutaminase 2. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Nuclear Medicine and Biology | en_US |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute | en_US |
dc.identifier.affiliation | School of Cancer Medicine, La Trobe University, Melbourne, Australia. | en_US |
dc.identifier.affiliation | Faculty of Medicine, The University of Melbourne, Melbourne, Australia | en_US |
dc.identifier.affiliation | Molecular Imaging and Therapy | en_US |
dc.identifier.affiliation | Faculty of Medicine, Eberhard Karls Universität Tübingen, Germany. | en_US |
dc.identifier.doi | 10.1016/j.nucmedbio.2022.11.002 | en_US |
dc.type.content | Text | en_US |
dc.identifier.pubmedid | 36502585 | - |
dc.description.volume | 116-117 | - |
dc.description.startpage | 108308 | - |
local.name.researcher | Ackermann, Uwe | |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.